A relationship between thyroid disease and breast cancer has been postulated for years. A geographic correlation between incidence of goiter and breast cancer has been noted (Bogardus & Finley, 1961; Eskin, 1970) , but a similar correlation between thyroid cancer and breast cancer was not observed (Waterhouse et al., 1976) . Several studies have demonstrated an increased risk of breast carcinoma in patients with thyroid dysfunction (Repert, 1952;  Humphrey ' & Swerdow, 1964) and thyroid cancer (Chalstrey & Benjamin, 1966; Shands & Gatling, 1970) , while others have shown either a slight, nonsignificant excess (Schottenfeld & Berg, 1971; Schoenberg, 1977) or none at all (Hedley et al., 1981; Hoffman & McConahey, 1981) . Thyroid function in breast cancer patients has been evaluated, also with contradictory results. Raised serum TSH (thyroid stimulating hormone) levels were observed in some studies (Mittra & Hayward, 1974; Rose & Davis, 1978) , but others could not confirm these findings (Adami et al., 1978; MacFarlane et al., 1980) . Recently there has been controversy concerning the role of thyroxine replacement therapy in the aetiology of breast cancer (Kapdi & Wolfe, 1976; Shapiro et al., 1980) . Iodine deficiency has been suggested as an aetiologic factor in follicular thyroid cancer (Williams, 1979) and possibly breast cancer (Stadel, 1976 ). An ecologic correlation between alcohol consumption and both thyroid and breast cancer has also been noted (Breslow & Enstrom, 1974; Williams, 1976) , but not confirmed in another study (Pochin, 1976 (Monson, 1974) . Ratios of observed to expected cancer cases (SIR) and 95% Fisher exact confidence limits were calculated assuming that the observed cases were distributed as a Poisson variate (Rothman & Boice, 1979 cIncludes treatment with post-menopausal hormones and endocrine surgery. was observed (Table II) . The most striking observation was a significantly increased risk in both series among women under age 40 years at diagnosis of the first primary (SIR: thyroid to breast=2.91; breast to thyroid=4.37) (Figure 1 ). In the breast to thyroid series, risk decreased with age at first primary, so that by age 55 no excess risk was seen. In the thyroid to breast series the elevated risk was seen in all ages, except in the 50-59 year group. An evaluation of absolute risk showed that in the breast to thyroid series the risk was highest in the under 40 group and decreased until there was no excess at age 60 +. In the thyroid to breast series, the risk was elevated in each group, but was highest in the under 40 and over 60 groups. The high rate of multiple primary breast and thyroid cancer in young women appears to be specific to these two sites. Women less than 40 years old at time of diagnosis of their first cancer comprised 41% of the 34 breast cancers following thyroid cancer and 21% of the 24 thyroid cancers following breast cancer. In contrast, only 29% of the other 63 Patients treated solely with surgery had a significant risk of developing breast cancer after thyroid cancer (SIR= 1.78), and thyroid after breast cancer (SIR= 1.76) (Table II) . Patients receiving radiation therapy (in all but one case as an adjunct to surgery), also had an elevated but non-significant risk (SIR: breast to thyroid series= 1.61), thyroid to breast series = 2.57). While it is known that the group of 116 thyroid patients coded as being treated with hormones does not include all of the patients receiving hormonal therapy, it still should be noted that they had a 5-fold risk of developing breast cancer (Observed = 4, Expected= 0.72, SIR=5.55; 95% confidence interval=1.51-14.22). In the breast to thyroid series, no excess risk was seen among the hormone treated patients.
Analysis by histologic type indicated that the highest risk of breast cancer was found among patients with follicular or mixed papillary and follicular thyroid cancer (Table III) Length of time between first and second primary was examined in both series. Zs that in the thyroid to breast series, the greatest risk occurred within 10 years after the first primary and thereafter declined. In the breast to thyroid series no clear pattern was seen, but risk was still elevated at 15 years after the first primary. Wofnen under 40 years of age had a particularly high risk in both series within 5 years following diagnosis of the first tumour. This pattern was not evident for the other age groups.
An examination by year of diagnosis of first primary revealed that in the thyroid to breast series there was a continual rise in risk, with an SIR of 1.28 between 1935-49; 1.81 between 1950-59; 2.02 between 1960-69 and 2.30 between 1970-78. In the breast to thyroid series, there was a similar trend until 1970, when the excess risk decreased slightly. (SIR: 1935-49=1.0; 1950-59=1.3; 1960-69=2.4; 1970-78=1.9 ). These patterns could be due to improved early diagnosis and survivorship which would put patients at risk of developing a second primary.
Discussion
In our study, occurrence of breast and thyroid multiple primaries was evaluated using data from the Connecticut Tumor Registry. A significantly elevated risk of thyroid cancer following breast cancer and breast cancer following thyroid cancer was demonstrated. This finding was even more notable when compared to the risks obtained for other sites. In the breast to thyroid series, the only other second primary sites with a significant SIR greater than 1.6 were contralateral breast cancer and ovarian cancer. For thyroid as the initial cancer, only kidney and pancreatic cancer had a significant SIR over 1.8. carcinoma. An enhanced risk of second tumours was evident for the entire period after diagnosis of the first primary, although it was highest within one year after diagnosis of the first primary. In patients with breast cancer as the first primary a higher than expected incidence of thyroid cancer was seen mostly within one year after the diagnosis of breast cancer. This may be due to the close medical surveillance of cancer patients which would increase the probability of early diagnosis of a second primary cancer. For patients with thyroid cancer as the first primary, excess risk was highest within the first 10 years. It is not likely that the second tumours occurring within the first year are due to metastases, since the breast is not a usual site of metastases for thyroid cancer (Heitz et al., 1976) and tumours metastasizing to the thyroid gland are rarely diagnosed as primaries (Meissner, 1978) .
Previous studies have provided weak evidence for a relationship between thyroid and breast cancer. Schottenfeld & Berg, (1971) , in their survey of multiple primaries, observed a non-significant increase of breast cancer following thyroid cancer. A significant excess of thyroid cancer following breast cancer was also reported, but the elevated risk was similar in magnitude to the general excess of second primaries. Schoenberg (1977) studied second primaries recorded in the Connecticut Tumor Registry between 1935-64 and noted no increase on the incidence of thyroid cancer following breast cancer (SIR=1.1) and an elevated but non-significant risk of breast cancer among patients with thyroid cancer (SIR= 1.8). Our study includes Schoenberg's data but adds 14 years of follow-up. The additional data now available demonstrate that the risk of thyroid and breast cancer occurring in either sequence in the same person, is statistically significant.
The finding that young women (under age 40) had the highest risk of developing either a second primary thyroid or breast cancer, is suggestive of an endocrine or genetic aetiology. Eight women were diagnosed with a third primary in addition to the breast and thyroid. Five of these 8 cases were 40 years of age or younger at the first primary. Four had a malignancy of the contralateral breast and one of the endometrium.
The high risk of breast cancer among women with follicular thyroid cancer, especially women under 40 years of age, suggests that histologic type is an important variable to study. Since the mean age of women with follicular cancer is somewhat older than women with papillary or mixed papillary-follicular type, it may be that young women with follicular thyroid cancer constitute a special subgroup with a different aetiology.
As previously mentioned, the data on treatment were limited since they included only therapy given within 4 months post-diagnosis of the first primary and because thyroid hormone therapy was not consistently coded. However, the short length of time between diagnosis of the first and second tumour is not consistent with a radiation effect.
Our findings suggests that breast and thyroid cancer may share certain aetiologic features. For instance, infertility has been associated with thyroid dysfunction (Hembree & Vande Wiele, 1978) and breast cancer (Cowan et al., 1981) and the associated hormonal imbalance may be a factor in the aetiology of both thyroid and breast cancer. Apart from radiation exposure, no other risk factors for thyroid cancer have been established and known breast cancer risk factors could, therefore, provide a direction for future studies of thyroid cancer.
